Articles published by AN2 Therapeutics, Inc.
![](https://mms.businesswire.com/media/20240816585924/en/1863965/5/AN2_Therapeutics_Press_Release_Logo.jpg)
AN2 Therapeutics Adopts Limited Duration Stockholder Rights Plan
August 16, 2024
Via Business Wire
Tickers
ANTX
![](https://mms.businesswire.com/media/20240813783660/en/1863965/5/AN2_Therapeutics_Press_Release_Logo.jpg)
![](https://mms.businesswire.com/media/20240808125351/en/1863965/5/AN2_Therapeutics_Press_Release_Logo.jpg)
![](https://mms.businesswire.com/media/20240514775764/en/1863965/5/AN2_Therapeutics_Press_Release_Logo.jpg)
![](https://mms.businesswire.com/media/20240328333538/en/1863965/5/AN2_Therapeutics_Press_Release_Logo.jpg)
![](https://mms.businesswire.com/media/20240212430072/en/1863965/5/AN2_Therapeutics_Press_Release_Logo.jpg)
![](https://mms.businesswire.com/media/20240130626235/en/1863965/5/AN2_Therapeutics_Press_Release_Logo.jpg)
Via Business Wire
Tickers
ANTX
![](https://mms.businesswire.com/media/20231109308786/en/1863965/5/AN2_Therapeutics_Press_Release_Logo.jpg)
AN2 Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business and Scientific Highlights
November 09, 2023
Via Business Wire
Tickers
ANTX
![](https://mms.businesswire.com/media/20231106781305/en/1863965/5/AN2_Therapeutics_Press_Release_Logo.jpg)
AN2 Therapeutics to Present at Upcoming Investor Conferences
November 06, 2023
Via Business Wire
Tickers
ANTX
![](https://mms.businesswire.com/media/20231018590682/en/1863965/5/AN2_Therapeutics_Press_Release_Logo.jpg)
![](https://mms.businesswire.com/media/20231010060919/en/1863965/5/AN2_Therapeutics_Press_Release_Logo.jpg)
AN2 Therapeutics to Present New Data for Epetraborole at IDWeek 2023
October 11, 2023
Via Business Wire
Tickers
ANTX
![](https://mms.businesswire.com/media/20230926590651/en/1863965/5/AN2_Therapeutics_Press_Release_Logo.jpg)
AN2 Therapeutics Signs Grant Agreement to Discover Novel, Boron Based Therapies for Tuberculosis and Malaria
September 26, 2023
Via Business Wire
Tickers
ANTX
![](https://mms.businesswire.com/media/20230913252729/en/1863965/5/AN2_Therapeutics_Press_Release_Logo.jpg)
![](https://mms.businesswire.com/media/20230815851416/en/1863965/5/AN2_Therapeutics_Press_Release_Logo.jpg)
AN2 Therapeutics Announces Pricing of $70.0 Million Underwritten Offering of Common Stock
August 15, 2023
Via Business Wire
Tickers
ANTX
![](https://mms.businesswire.com/media/20230810314462/en/1863965/5/AN2_Therapeutics_Press_Release_Logo.jpg)
AN2 Therapeutics Reports Second Quarter 2023 Financial Results and Recent Highlights
August 10, 2023
Via Business Wire
Tickers
ANTX
![](https://mms.businesswire.com/media/20230525005314/en/1447127/5/an2_therapeutics_logo_weba_%28003%29.jpg)
Via Business Wire
Tickers
ANTX
![](https://mms.businesswire.com/media/20230510006124/en/1447127/5/an2_therapeutics_logo_weba_%28003%29.jpg)
Via Business Wire
Tickers
ANTX
![](https://mms.businesswire.com/media/20230501005119/en/1694868/5/an2_therapeutics_logo_weba_%28003%29.jpg)
Via Business Wire
Tickers
ANTX
![](https://mms.businesswire.com/media/20230328005954/en/1447127/5/an2_therapeutics_logo_weba_%28003%29.jpg)
AN2 Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Highlights
March 29, 2023
Via Business Wire
Tickers
ANTX
![](https://mms.businesswire.com/media/20230228006237/en/1694868/5/an2_therapeutics_logo_weba_%28003%29.jpg)
AN2 Therapeutics to Participate in Upcoming Investor Conferences
February 28, 2023
Via Business Wire
Tickers
ANTX
![](https://mms.businesswire.com/media/20230131005415/en/1694868/5/an2_therapeutics_logo_weba_%28003%29.jpg)
Via Business Wire
Tickers
ANTX
![](https://ml.globenewswire.com/media/caafb35e-ab8e-45e0-a580-016c3e869a55/small/an2-linkedin-2-jpg.jpg)
AN2 Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Updates
November 09, 2022
Via GlobeNewswire
Tickers
ANTX
![](https://ml.globenewswire.com/media/caafb35e-ab8e-45e0-a580-016c3e869a55/small/an2-linkedin-2-jpg.jpg)
AN2 Therapeutics to Present at Upcoming Investor Conferences
November 02, 2022
Via GlobeNewswire
Tickers
ANTX
![](https://ml.globenewswire.com/media/caafb35e-ab8e-45e0-a580-016c3e869a55/small/an2-linkedin-2-jpg.jpg)
AN2 Therapeutics to Present New Epetraborole Data at IDWeek 2022
October 19, 2022
Via GlobeNewswire
Tickers
ANTX
![](https://ml.globenewswire.com/media/244a98ea-f1aa-4e63-a545-015333e9d8dd/small/an2-therapeutics-logo-weba-jpg.jpg)
![](https://ml.globenewswire.com/media/244a98ea-f1aa-4e63-a545-015333e9d8dd/small/an2-therapeutics-logo-weba-jpg.jpg)
NIH Awards Contract to AN2 Therapeutics Valued Up to $17.8 Million
September 29, 2022
Via GlobeNewswire
Tickers
ANTX
![](https://mms.businesswire.com/media/20220509005229/en/1447136/5/an2_therapeutics_logo_weba_%28003%29.jpg)
Via Business Wire
Tickers
ANTX
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.